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Purpose: To compare the clinical outcome of males with low-risk and favorable intermediate-risk prostate cancer managed within 
a standardized modern protocol of active surveillance.
Materials and Methods: This was a prospective cohort study with strict and expanded active surveillance criteria in males with 
prostate cancer. Baseline assessment included multiparametric magnetic resonance imaging (mpMRI), extended systematic bi-
opsy, and software-based MR-targeted biopsy. Follow-up included biannual prostate-specific antigen (PSA) check, mpMRI, and 
control biopsy once a year for the first 2 years, and afterward mpMRI every 2 years with additional tests as clinically indicated. The 
primary outcome was the transition rate to active treatment.
Results: A total of 51 patients were included: 17 (33%) and 34 (67%) followed protocols of strict (study arm 1) and expanded (study 
arm 2) active surveillance criteria, respectively. Median age and PSA were 65 years (IQR, 60–69 years) and 5.3 ng/mL (IQR, 4.5–7.7 
ng/mL), respectively. At baseline, a median of 2 (IQR, 1–3) cores were positive out of 13 (IQR, 12–14) cores; 22 males (43%) had vis-
ible mpMRI lesions. Eight males (24%) in study arm 2 had Gleason score 3+4. After a median follow-up of 36 months (IQR, 24–48 
mo), no patient in study arm 1 compared with 17 patients (33%) in arm 2 underwent active treatment (p<0.0005). 
Conclusions: Although expanding eligibility criteria leads to a greater transition rate to active treatment, active surveillance 
should be contemplated in well-selected males with favorable intermediate-risk prostate cancer as the curability window seems to 
be maintained.
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INTRODUCTION
Level 1 evidence shows that active surveillance (AS) is a 
valid option for males with low-risk prostate cancer (PCa) [1]. 
Historically, strict criteria have been applied to select males 
eligible for an AS policy to minimize the risk of missing the 
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curability window. The clinical criteria used most often to 
define such eligibility are the Epstein criteria [2], which were 
developed two decades ago by use of transrectal ultrasound-
guided (TRUS) systematic random biopsy. These criteria 
were defined by considering the random nature of TRUS 
biopsy. Thus, to minimize the risk of underestimating cancer 
burden and grade, the thresholds for defining significant 
disease were set very low.
We are now able to reject the role of  TRUS random 
biopsy in risk-stratifying males because the diagnostic accu-
racy of this test has finally been quantified. The sensitivity 
of TRUS biopsy to detect clinically significant PCa was esti-
mated at 48% in a recent paired validation diagnostic study 
[3]. The consequences are twofold: TRUS systematic random 
biopsy should not be used to define eligibility for AS and the 
Epstein criteria should not be arbitrarily applied to define 
eligibility for AS when accurate diagnostic tests are used.
However, a curious situation has arisen. Despite strong 
evidence suggesting that AS should be offered to many 
males diagnosed with localized PCa, few are eligible if 
modern diagnostic tests are used. Level 1 evidence shows 
that at a median follow-up of 10 years, the mortality from 
PCa is approximately 1%, irrespective of whether males are 
followed by AS or undergo active treatment [4]. As a con-
sequence, AS should be reasonably offered to the majority 
of males with low-risk disease. However, our tools for risk 
stratification have changed, and TRUS random biopsy alone 
is no longer the standard of care. The use of multiparamet-
ric magnetic resonance imaging (mpMRI) and MR-targeted 
plus TRUS systematic biopsy at baseline is more sensitive 
for detecting clinically significant disease. This inevitably 
leads to more males being assigned to a higher risk category 
and thus being considered ineligible for AS [5]. 
Many have therefore proposed expanding the criteria 
for AS since our diagnostic tools are changing but not the 
disease itself. Prospective studies evaluating the outcome 
of males with intermediate-risk features followed within 
AS suggest that although these males are at higher risk of 
transition to treatment, the vast majority do not compromise 
the chance of long-term cure [1,6]. Notably, these series did 
not include baseline MRI risk stratification and therefore 
are hindered by the limitations mentioned above.
The main objective of  this study was to compare the 
clinical outcome of AS in patients with strict and expanded 
criteria in a modern prospective AS cohort incorporating 
MRI and MR-targeted biopsy at baseline and at follow-up in 
a standardized protocol. 
MATERIALS AND METHODS
1. Design and inclusion criteria
This was a prospective research ethics committee-ap-
proved (Cantonal Commission on Ethics in Human Research 
[CER-VD]) multiple-arm cohort study (approval number: 
NCT01795365, date of  registration: 20/02/2013). Informed 
written consent was obtained from all study subjects. The 
aim of this study was to compare the clinical outcome of AS 
with the use of strict and expanded criteria in patients har-
boring low to favorable intermediate-risk PCa, respectively. 
Eligible patients were assigned to two groups according to 
disease features at baseline: strict criteria (study arm 1, or 
control arm) and expanded criteria (study arm 2, or inter-
ventional arm). The eligibility criteria are listed in Table 1. 
When choosing the upper threshold for cancer burden in bi-
opsy in study arm 2, we fixed the maximum length thresh-
old at 8 mm because this corresponds to the upper relevant 
lesion diameter suggested within a randomized screening 
trial [7]. Patients not meeting all the strict AS criteria were 
assigned to the interventional arm (study arm 2).
2. Follow-up
Both groups underwent identical diagnostic assessment 
at baseline and follow-up (Table 2). Baseline assessment in-
cluded prostate-specific antigen (PSA) check, digital rectal 
examination, mpMRI, and extended random and MR-tar-
geted biopsy. The follow-up included PSA assessment twice 
a year, mpMRI and control biopsy once a year for the first 
2 years, and thereafter mpMRI every 2 years. According 
to PSA variation or imaging change, additional tests were 
performed, as clinically indicated. Transition to active treat-
ment was advised in males whose disease progressed beyond 
the expanded eligibility criteria. Transition from study arm 
1 to study arm 2 or progression within each arm was per-
mitted; it was not an indication for active treatment per se, 







PSA (ng/mL) <10 <15 
Gleason score 3+3=6 ≤3+4
No. of positive biopsies ≤3 ≤5
Maximum cancer burden ≤3 mm and <50% 
invasion
≤8 mm
mpMRI PI-RADS score 1–3 4–5
PSA, prostate-specific antigen; mpMRI, multiparametric magnetic 





although this was discussed according to the local standard 
of care in cases of disease progression in males under AS. 
MpMRI and the biopsy protocol were standardized. Pros-
tate mpMRI was acquired and interpreted according to the 
Prostate Imaging Reporting and Data System (PI-RADS) 
score and was reported by a single expert radiologist. A 3T 
magnetic field strength with an endorectal coil was used, 
including T1-weighted sequences, T2-weighted sequences, dif-
fusion-weighted imaging (DWI) with corresponding apparent 
diffusion coefficient maps, and dynamic contrast-enhanced 
sequences. Prior to biopsy, all mpMRI data were reviewed in 
a dedicated uro-radiology meeting where the radiologist an-
notated all lesions with PI-RADS scores ≥3. 
Delineated T2-weighed and DWI sequences were up-
loaded into the KOELIS Urostation (Koelis, Meylan, France). 
At the time of biopsy, the prostate contour was defined by 
using semi-automatic embedded software. A TRUS end-
fire probe was used to acquire three-dimensional images 
using the Samsung Ultrasound UGEO 60 (Samsung Me-
dison, Seoul, Korea). Afterward, axial TRUS images were 
contoured and elastic-fusion was performed. All patients 
underwent MR-targeted biopsy with 2 to 4 needles deployed 
per target followed by 10–12-core standard biopsy. If  the 
MR target was located in the peripheral sextant sampled by 
standard biopsy, additional random sampling in the same 
area was omitted. All biopsies were performed by two expert 
consultant urologists.
When active treatment was prompted, patients were 
managed as per the standard of care in the local Prostate 
Cancer Unit. Treatment options were offered as part of a 
multidisciplinary approach considering relevant clinical 
criteria as well as the patients’ values. Focal therapy was 
offered using high frequency focused ultrasound (HIFU) 
or cryotherapy; radical prostatectomy (RP) was proposed 
in an open or laparoscopic robotic-assisted fashion; external 
radiotherapy was proposed by using a standard protocol or a 
hypofractionated scheme within a recently reported prospec-
tive study [8].
The follow-up protocol after active treatment was stan-
dardized. Patients who underwent RP or radiotherapy were 
routinely followed up as recommended by the EAU guide-
lines. Patients undergoing focal therapy also underwent a 
standardized follow-up within a prospectively maintained 
registry; failure of focal therapy was defined as any residual 
or recurrent clinically significant disease (≥3+4), secondary 
local treatment, PCa-related death, or transition to meta-
static disease.
3. Statistical analysis
The overriding hypothesis of this study was that by us-
ing precise tools of assessment at baseline, the transition to 
active treatment would not differ significantly between the 
two groups after 6 years of follow-up. The power calcula-
tion was adjusted based on the study by Cooperberg et al. [9], 
which indicated the rates of transition to active treatment 
as 30% and 35% for patients risk-stratified by random bi-
opsy and followed by active monitoring with the use of low- 
and intermediate-risk criteria, respectively. With 80% power 
and a two-sided α level of 5%, the study sample size was 45 
patients in each group, allowing an estimated difference of 
15% between groups. Considering a 10% dropout rate, the 
final sample size was 50 patients per group. We estimated 
a recruitment time of 5 years; the analysis in the present 
study was performed after this time frame. Group differ-
ences in categorical variables and continuous variables were 
analyzed with chi-square tests and Kruskal–Wallis tests, re-
spectively. The difference in duration of AS between groups 
was measured by using Kaplan–Meier survival plots. Poten-
tial predictors of active treatment were analyzed by univari-
able and multivariable Cox proportional hazards regression 
analysis. All statistical tests were two-sided with significance 
set at a p-value of <0.05. All analyses were conducted with 
Stata 15 (StataCorp, College Station, TX, USA).
RESULTS
At the time of this analysis (November 2018), 51 patients 
were enrolled: 17 (33%) had strict and 34 (67%) had expanded 
criteria. The CONSORT flow diagram is presented in Fig. 
1. Clinical and pathologic characteristics of the patients are 
Table 2. Follow-up chart of the patients included in our study
Diagnostic 
test
-6 to 0 Consent 6 12 18 24 30 36 42 48 54 60 66 72
PSA X X X X X X X X X X X X X
DRE X X X X X X X
mpMRI X X X X X
Biopsies X X X
PSA, prostate-specific antigen; DRE, digital rectal examination; mpMRI, multiparametric magnetic resonance imaging.
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shown in Table 3. The patients’ median age and PSA at 
diagnosis were 65 years (interquartile range [IQR], 60–69 
years) and 5.3 ng/mL (IQR, 4.5–7.7 ng/mL), respectively. A 
median of 2 cores (IQR, 1–3) were positive out of 13 cores 
(IQR, 12–14) at baseline. The patients’ age, PSA, and clinical 
stage were similar between groups. Patients with expanded 
criteria had more cancer burden at the baseline biopsy in 
terms of the number of biopsies with cancer, the percentage 
of biopsies with cancer, the maximum cancer burden in a 
single core, the total cancer core length, and the maximum 
cancer core length (MCCL) in a single biopsy. Median follow-
up time was 3 years (IQR, 24–48 months).
Overall, 17 patients (33%) underwent active treatment 
within the study time frame; all of them had been assigned 
to study arm 2 (p=0.0005; Fig. 2). Median time to active 
treatment was 12 months (IQR, 6–36 months). Reasons for 
active treatment were Gleason score progression (n=6, 35%), 
tumor volume progression (n=7, 41%), mpMRI progression 
(n=3, 18%), and patient’s decision (n=1, 6%). However, only 
nine patients experienced progression beyond the expanded 













Excluded from analysis (n=0)
Analysed (n=34)





Fig. 1. CONSORT flow diagram. AS, active surveillance; RP, radical pros-
tatectomy.







Number of patients 51 (100) 17 (33) 34 (67) -
Age (y) 65 (60–69) 64 (60–69) 66 (62–69) 0.3
PSA baseline (ng/mL) 5.3 (4.5–7.7) 5.2 (3.4–6) 5.6 (4.5–8.1) 0.8
PSA density (ng/mL/cm3) 0.16 (0.1–0.2) 0.11 (0.1–0.2) 0.18 (0.1–0.3) 0.2
Clinical tumor stage 0.3
   cT1a 7 (14) 4 (23) 3 (9)
   cT1c 39 (76) 12 (70) 27 (79)
   cT2a 5 (10) 1 (7) 4 (12)
Baseline PIRADS score <0.01
   1–3 29 (57) 17 (100) 12 (35)
   4–5 22 (43) 0 (0) 22 (65)
Prostate volume (mL) 33 (23–52) 33 (20–54) 34 (23–50) 0.2
Number of mpMRI suspicious lesions 1 (0–1) - 1 (0.3–1.8) 0.1
Maximum lesion diameter on mpMRI 9 (6–13) - 9 (6–13) -
Gleason score 0.3
   3+3=6 43 (84) 17 (100) 26 (76)
   3+4=7 8 (16) 0 (0) 8 (24)
No biopsy taken 13 (12–14) 12 (12–13) 13 (11–15) 0.2
No biopsy with cancer 2 (1–3) 1 (1–2) 2.5 (1–4) 0.02
% of biopsies with cancer 4.3 (1–5) 1 (1–2.5) 5 (2–5.5) 0.05
Maximum cancer burden in a single core % 16 (8.5–30) 8 (5–15) 21.5 (14.8–30) 0.01
Total cancer core length (mm) 4 (2–8) 1.75 (1–2.8) 5 (3–10) 0.03
Maximum cancer burden in a single core length (mm) 2.5 (1–4) 1 (1–1.8) 3 (2–4.8) 0.03
Values are presented as number (%) or median (interquartile range).




biopsy and/or MCCL >8 mm), and two in terms of Gleason 
score (Gleason 4+3). Ten patients (59% of treated patients) 
underwent RP, three (17%) patients underwent external 
beam radiotherapy, and four (24%) patients underwent focal 
therapy.
Of the remaining patients who remained on surveillance, 
seven progressed from study arm 1 to study arm 2. Five pa-
tients progressed because of mpMRI score upgrade, and two 
patients progressed because of tumor volume progression in 
the biopsy. Three patients in study arm 2 chose to continue 
AS despite the violation of one inclusion criteria. They all 
had PSA levels above 15 ng/mL with other criteria remain-
ing within the admitted thresholds.
Overall survival, disease-specific survival, and metastasis-
free survival were 100%. Among 10 patients who underwent 
RP, 7 (70%) had T2c disease and 3 (30%) had T3a; none had 
positive nodes, and one patient had positive margins. Two 
(20%) had Gleason 3+3=6 disease, seven patients (70%) had 
Gleason 3+4=7, and one (10%) had Gleason 4+3=7 disease. 
Among all treated patients, including those undergoing 
radiation therapy and focal therapy, none had local failure 
after a median follow-up of 23 months after treatment (IQR, 
4–30 months).
Baseline variables potentially predictive for transition 
to active treatment are shown in Table 4. In the univariate 
analysis, PI-RADS score, Gleason score, and MCCL in the bi-
opsy seemed relevant predictors of transition to active treat-
ment. In the multivariate analysis, only PI-RADS score and 
MCCL remained independent predictors.
DISCUSSION
To our knowledge, this is the first prospective trial 
comparing the clinical outcomes of patients with low- and 
intermediate-risk PCa using a structured protocol embed-
ding mpMRI and MR-targeted biopsies. In brief, we found 
that AS is a valid option for selected intermediate-risk pa-
tients. At 3 years, overall, disease-specific, and metastasis-free 
survival were all 100% in our study, as expected. Although 
males with expanded criteria were at greater risk for pro-
gression, the window of curability was maintained. PI-RADS 
score and MCCL were independent predictors for active 
treatment, underlining the importance of a mpMRI-based 
pathway. 
The primary hypothesis of this trial—a similar transi-
tion rate in the two groups—was clearly not met; prolonged 
follow-up is unlikely to change this as the difference be-
tween the two groups was too wide and also considering 
the available sample size (p=0.0005). Based on the findings 
of this study, the steering committee amended the initial 
protocol in 2020: the trial has been modified to a single-
cohort study whose objective is to enable the discovery of 
candidate biomarkers to identify males early who stand to 
benefit from active therapy and to avoid intervention in 
those for whom active therapy is not necessary. The novel 

































Time to active treatment
Arm 1: strict criteria
Arm 2: expanded criteria
p=0.0005
Time in months
Fig. 2. Kaplan–Meier curve of time to active treatment.










Age 1.05 0.96–1.15 0.30
PSA baseline 1.02 0.89–1.17 0.78
PSA density 2.17 0.16–478 0.28
PI-RADS score 1.70 1.11–2.63 0.02 1.78 1.06–3.02 0.03
Gleason score 2.24 0.79–6.36 0.13 2.15 0.65–7.12 0.21
Max cancer core length 1.24 1.06–1.44 0.01 1.22 1.05–1.43 0.01
No biopsy with cancer 1.03 0.76–1.40 0.20
PSA, prostate-specific antigen; PI-RADS, Prostate Imaging Reporting and Data System.
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purpose. While all males choosing AS are enrolled in this 
cohort study, in concordance with the findings of this study, 
patients are informed about the accrued risk of transition to 
active treatment according to baseline characteristics (Glea-
son score and cancer burden).
Comparing our results with others, 21% of 993 males in 
the Sunnybrook cohort had intermediate-risk features; tran-
sition to active treatment was 8% [10] with baseline PSA lev-
els and Gleason score at 1 year associated with failure. This 
differs from our baseline predictors and active treatment 
rate. The differences might be due to the different study 
designs: our study included mpMRI from baseline, whereas 
in the Sunnybrook series mpMRI was not used routinely. 
Cooperberg et al. [9] published a series of 540 males with in-
termediate-risk features managed with AS. After a median 
of 4 years of follow-up, the number of males presenting with 
clinical progression was not significantly different between 
the intermediate-risk (61%) and low-risk (54%) groups (p=0.22). 
In contrast, patients in our cohort with a PI-RADS score of 
1 to 3 and low-volume and low-grade disease had no risk of 
quitting AS during the study time frame. This strongly sug-
gests that in males with low-risk disease and negative re-
sults on mpMRI, the rate of progression is extremely low. In 
the Prostate Cancer Active Surveillance Study of 115 males 
with intermediate-risk disease (13% of the cohort) [11] after a 
median follow-up period of 28 months, 24% of the entire co-
hort experienced disease reclassification defined by a higher 
Gleason grade or tumor volume on repeat biopsy. In our 
study in which we employed similar criteria for transition 
to radical therapy, the results were analogous: 26% of the 
males in study arm 2 were reclassified beyond the admitted 
thresholds of expanded AS criteria.
When assessing those males who underwent RP, our 
data also indicate the safety of deferred RP as none of our 
patients had unfavorable pathological features, namely, 
Gleason ≥4+4, seminal vesicle invasion, or positive lymph 
nodes. Furthermore, none of them developed biochemical 
relapse after a median follow-up of 2 years. In the AS series 
from the Royal Marsden, which included 88 males with 
intermediate-risk disease, after a median follow-up of 5.7 
years, 43 males underwent deferred RP [12]. Of these, 4 (9%) 
had Gleason score ≥4+4, 6 (14%) had pT3 disease, and 14 (33%) 
had positive margins. In a Swedish nationwide population-
based study, 7,608 males with low-risk disease features had 
either delayed or immediate prostatectomy [13]. Males un-
dergoing RP more than 2 years after their diagnosis had 
a higher risk of Gleason upgrading and increased risk for 
salvage radiotherapy with no significant increase in PCa-
specific mortality. These studies once again suggest that 
upgrading to unfavorable disease in RP specimens might be 
the result of initial underestimation of disease rather than 
true disease progression, as the upgrading was based on sys-
tematic TRUS biopsy without the use of MRI. 
Multiple studies have addressed the importance of 
mpMRI in AS. Our data suggest that mpMRI plays a key 
role when predicting failure-free survival. Also, MCCL in 
the biopsy predicts active treatment better than the Glea-
son score. This is likely related to imaging, as targeting the 
center of a lesion leads to greater MCCL than do systematic 
nontargeted biopsies. Sanguedolce et al. [14] reported similar 
findings for 135 prospective patients selected for AS by use 
of  the Epstein criteria with mpMRI performed within 3 
months of recruitment in AS. At a median follow-up of 31 
months, the variables significantly associated with failure-
free survival were the index lesion size and overall PI-RADS 
score. Thurtle et al. [15] published early outcomes from a pro-
spective AS series incorporating image-guided baseline risk 
assessment and mpMRI-based follow-up in patients with 
favorable-risk disease. That study confirmed our findings, 
showing low rates of conversion to active treatment (11.7%) 
over a median 3.3 years of follow-up.
There are some limitations to our study. The minimum 
sample size per group was not met during the recruitment 
period. This was due to many males being followed with AS 
but not being eligible for this study and to other males un-
expectedly choosing to be followed off-trial. Also, the groups 
were not balanced, with two-thirds of the study population 
assigned to the interventional arm. This may have been the 
result of our more accurate diagnostic pathway, with many 
males for whom AS could be the preferred option considered 
ineligible if strict eligibility criteria were systematically ap-
plied. It also highlights the changing landscape of PCa in 
the modern era with stage migration occurring from the 
use of MRI and targeted biopsies. The small sample size also 
limits the power of our multivariable analysis including five 
variables. Finally, the median follow-up was short. Prolonged 
follow-up is necessary to confirm the oncological outcome of 
AS across the two groups.
CONCLUSIONS
Expanding the criteria for AS seems to increase the rate 
of transition to active treatment. Nonetheless, in the short 
term, the curability window is maintained. PI-RADS score 
and cancer burden seem the most relevant predictors of dis-
ease progression. Confirmatory studies in larger cohorts with 
longer follow-up are urgently needed to safely broaden the 
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